Thread by @cperruna

Stocks to Watch in 2019
50 weeks in, + 42.03%

$COUP +123.5%
$TTD +117.5%
$STNE +114.3%
$PAYC +109.9%

$OKTA +82.9%
$IMMU +44.9%
$TEAM +34.7%
$TWLO +9.7%
$BJ +6.5%
$TWTR +5.7%

$ALRM -18.2%
$CGC -23.0%
$NIO -62.5%

1/1/19 Blog Post: chrisperruna.com/2019/01/01/sto…

$COUP $140.46, +123.5% YTD
Earnings are positive & sales have increased from $53.8MM to $101.8MM over the past 8 qtrs.

The stock has been building a base the past 5 months above the 200d ma. Accumulate near the 200d for the next potential run.

$TTD $252.45, +117.5% YTD
Earnings growth has slowed but sales growth is still logging it as 38% YoY for the latest quarter.

A five month cup shaped base is currently underway above the 200d ma. Accumulation can take place near the 200d or after a handle formation breakout.

$STNE $39.53, +114.3% YTD
Sales growth was 70% last qtr vs previous year while revenue growth remains over 50% QoQ.

Buffett is one of the largest holders of the stock but I'd like to see greater institutional support, which is needed to propel this stock higher.

$PAYC $256.99, +109.9% YTD
Looks to forming a high handle following the three month cup shaped base.

Accumulation near the 200d ma has proven to be profitable for the past three years.

$OKTA $116.69, +82.9% YTD
The stock is in the midst of a 5 month base as it sits on the 200d ma. The ideal area to accumulate.

Sales have increased from 77.1MM to $153.0MM the past eight quarters but the company needs to turn a profit.

$IMMU $20.67, +44.9%
The company resubmitted their drug application to the FDA after a rough year, following rejection in January.

The stock dropped nearly 40% during the year but has since gained 78% from lows. As I said Jan 1, it's all about FDA approval = revenue.